A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

BACKGROUND: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. METHODS: This phas...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Exp Hematol Oncol
Prif Awduron: Ichinohe, Tatsuo, Kuroda, Yoshiaki, Okamoto, Shinichiro, Matsue, Kosei, Iida, Shinsuke, Sunami, Kazutaka, Komeno, Takuya, Suzuki, Kenshi, Ando, Kiyoshi, Taniwaki, Masafumi, Tobinai, Kensei, Chou, Takaaki, Kaneko, Hitomi, Iwasaki, Hiromi, Uemura, Chie, Tamakoshi, Hiromi, Zaki, Mohamed H., Doerr, Thomas, Hagiwara, Shotaro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2016
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4835896/
https://ncbi.nlm.nih.gov/pubmed/27096106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-016-0040-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg